| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Careteam Plus provides compassionate, inclusive general and specialty health care for adults, teens, and children in Conway near CCU.
Bright Pharmaceutical Services is a Sherman Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors to help patients with cancer live longer and better.
Validation & Engineering Group is a Guaynabo, PR-based company in the Healthcare, Pharmaceuticals, & Biotech sector.